Research programme: glucagon-like peptide-1 receptor modulators - Addex Therapeutics

Drug Profile

Research programme: glucagon-like peptide-1 receptor modulators - Addex Therapeutics

Alternative Names: GLP-1 PAM; GLP-1R PAM

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Therapeutics
  • Class Small molecules
  • Mechanism of Action Glucagon-like peptide 1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 06 Dec 2016 Preclinical for Type-2 diabetes mellitus in Switzerland (PO) before December 2016 (Addex Therapeutics pipeline, December 2016)
  • 06 Dec 2016 GLP1R PAM is still in preclinical studies for Type-2 diabetes mellitus in Switzerland (PO) (Addex Therapeutics pipeline, December 2016)
  • 13 Feb 2013 No development reported for Type-2 diabetes mellitus in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top